ArticleEJHaem2024
Real-life data of luspatercept in lower-risk myelodysplastic syndromes advocate new research objectives.
Bert Heyrman et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
3 papers cite it
this paperpooled itcites it